#China #Guangzhou #VectorBuilder #Sartorius #Biopharma

Collaborative Advances in Biopharmaceutical Innovation

VectorBuilder, recognized globally for its comprehensive gene delivery services, has officially partnered with Sartorius, a prominent name in life sciences. This strategic alliance is set to revolutionize the biopharmaceutical landscape by honing in on gene vector and mRNA bioprocess solutions. By merging their expertise, the two companies aim to expedite the development and clinical application of novel biopharmaceuticals.

Building on a track record of successful collaboration, this partnership will expand into vital areas essential for the growth of gene and cell therapies. Key initiatives include co-developing advanced downstream processes designed specifically for these therapies, as well as optimizing the development and commercial production of GMP-compliant mRNA, plasmid, and viral vectors. Furthermore, both companies are committed to realizing sustainability goals through this collaboration and will focus on the education and training of talent within their teams.

Sarah Wang, Head of Sartorius China, highlighted the importance of customer-centric innovation as a guiding principle in their efforts. With this cooperative agreement, the companies are optimistic that they will create innovative solutions that enhance the efficiency and quality of operations within the biomedical sector. The anticipated outcome is to support their collective global customer base while contributing significantly to advancements in life sciences.

Echoing this sentiment, Dr. Bruce Lahn, Founder and Chief Scientist of VectorBuilder, expressed enthusiasm about the potential this agreement holds for the research community and pharmaceutical entities worldwide. By combining unique capabilities, both organizations will create a more effective and streamlined biopharmaceutical ecosystem.

Michaela Pischke, Head of the Business Area Separation Technologies at Sartorius, also echoed similar sentiments, emphasizing that leveraging each company's strengths is key to enabling innovation in downstream processing. This innovation aims to shorten time to market, which can ultimately lead to the delivery of life-saving treatments.

Together, Sartorius and VectorBuilder are keen on exploring the enormous potential stored within cell and gene therapies, and they are dedicated to accelerating the application of research breakthroughs into actionable medical treatments that can save lives. Both companies remain focused on contributing to the global biomedical field by ensuring that transformative processes come to fruition.

About the Companies

Sartorius is a key player in the biopharmaceutical and laboratory industries, providing innovative technologies and solutions to drive success in life sciences research. VectorBuilder is also a leader in gene delivery services, specializing in making advanced genetic engineering accessible for research and therapeutic initiatives. The strategic partnership marks an important step towards delivering greater innovation and efficiency in biopharmaceutical development.

This cooperation sets a precedent for future innovations that will significantly impact the field of biopharmaceuticals and ultimately enhance the quality of life on a global scale.